CompletedEUCTR 2005-002131-27
Efficacy and safety of eslicarbazepine acetate (BIA 2-093) in acute manic episodes associated with Bipolarity type I in a double-blind, randomised, dose-titration, placebo-controlled, multicenter ...
This historical record does not confirm current site availability.
Historical research recordMultiple countries
Understand this study
What did researchers investigate?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
Who was this study for?
This study was for people with type I bipolarity. Other eligibility criteria applied.
- Listed locations
- Austria · Czechia and 3 more locations
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateNot clearly listed
- Recruitment status
- Completed
- Enrollment listed in the registry
- 160
- Sponsor
- BIAL - Portela & Ca, S.A.
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- Austria, Czechia, Germany, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2005-002131-27
- Official title
Show the full official title
Efficacy and safety of eslicarbazepine acetate (BIA 2-093) in acute manic episodes associated with bipolar I disorder in a double-blind, randomised, dose-titration, placebo-controlled, multicenter ...
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Austria · Czechia · Germany
2 more locations
- Portugal
- Slovakia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is BIAL - Portela & Ca, S.A.
Who was this study for?
This study was for people with type I bipolarity. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate the Efficacy and Safety of Adjunctive Aripiprazole Therapy in the Treatment of Mania in Bipolarity type I Pat...
A 24-Week, Flexible-Dose, Open-label Extension Study of Lurasidone for the Treatment of Bipolar I Depression